semaglutide hepatic impairment child pugh AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update Semaglutide 2·4 mg once weekly

When combined, these effects may amplify weight loss results beyond what either medication can achieve alone

although NAION events were rare among GLP-1 receptor agonist users, the possibility of small risk differences, particularly with specific agents or in selected high-risk patients, remains clinically relevant. The biological relationship between GLP-1 agonist therapy and optic nerve ischemia remains uncertain

Medical supervision can decrease these risks to help make your weight loss journey safe

Lifestyle Factors Exercise, nutrition, sleep, and stress management all influence the rate of senescent cell accumulation and the body's capacity for tissue repair

The main surprising element was that this patient was taking as much vitamin D as possible to strengthen the bones but was not aware that there was a risk of toxicity with extremely large doses